In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL/lpr-lpr mouse

Immunopharmacology. Jul-Aug 1992;24(1):11-6. doi: 10.1016/0162-3109(92)90064-j.

Abstract

The effects of the in vitro treatment with a mAb (DB-1) that neutralizes mouse IFN-gamma on the development of the SLE-like syndrome in MRL/lpr-lpr (MRL-lpr) mice were studied. The results show that the i.p. administration of 2.6 mg/week of DB-1 from the 12th to the 20th week of age neither affected the survival nor the incidence and severity of lupus nephritis in MRL-lpr mice. This study argues against the pathogenic relevance of IFN-gamma in this experimental model of human SLE.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Autoimmune Diseases / complications*
  • Autoimmune Diseases / pathology
  • Autoimmune Diseases / therapy
  • Disease Models, Animal
  • Female
  • Interferon-gamma / immunology
  • Interferon-gamma / physiology*
  • Lupus Erythematosus, Systemic / etiology
  • Lupus Erythematosus, Systemic / therapy
  • Lupus Nephritis / etiology*
  • Lymphoproliferative Disorders / complications*
  • Lymphoproliferative Disorders / pathology
  • Lymphoproliferative Disorders / therapy
  • Mice

Substances

  • Antibodies, Monoclonal
  • Interferon-gamma